東阿阿膠(000423.SZ)一季度預盈5548萬-7213萬元 同比扭虧為盈
格隆匯 4 月 14日丨東阿阿膠(000423.SZ)公佈,預計2021年度第一季度歸屬於上市公司股東的淨利潤5548萬元-7213萬元,上年同期虧損8387萬元。
公司堅持以消費者為中心,專注顧客運營,加速數字化轉型,建立新增長邏輯;逐步提升組織能力,穩步推進技術創新、產品創新、營銷創新和品牌煥新,為消費者健康持續創造價值。
未來,公司聚焦顧客增長與保留,實現拓增量、築品牌,鞏固核心產品市場領導地位,促進市場良性增長;同時,鞏固中式滋補健康引領者地位,釋放品牌生產力,向消費者提供方便、年輕、時尚的產品體驗和服務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.